Diagnostic and Prognostic Role of Elafin in Skin Acute Graft Versus Host Disease: a Systematic Review
Source : https://pubmed.ncbi.nlm.nih.gov/38112182/
Elafin is a significant biomarker for diagnosis and prognosis of skin aGVHD and should be assessed within 2 weeks of the onset of the disease.
Elafin can potentially be the specific biomarker associated with the diagnosis and prognosis of skin acute GVHD and it should be investigated within 14 days of onset of acute GVHD.
Separation of GVL From GVHD - Location, Location, Location
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728488/
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for various hematologic malignancies.
Specific inhibition of donor T-cell migration to GVHD target tissues while preserving migration to the bone marrow may represent a novel strategy to separate GVL from GVHD.
Adherence to Immunosuppressants Among Adult Patients After Allogeneic Hematopoietic Stem-Cell Transplantation (Allo-HSCT): a Cross-Sectional Study
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10700097/
Background: The level of adherence to drug therapy after allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) can affect the patient's outcome, and poor adherence is one of the factors in first-year mortality...
Cyclosporine plays the most important role after the allo-HSCT period since it prevents GVHD, and this study indicated that blood level directly correlates with patient adherence. With 1 score increase, the cyclosporine level also rises about 35 ng/mL on average.
A Personalized, Organ-Based Approach to the Treatment of Chronic Steroid-Refractory Graft-Versus-Host Disease
Source : https://www.sciencedirect.com/science/article/abs/pii/S0268960X23001030?via=ihub
Chronic graft-versus-host-disease (cGvHD) remains the leading cause of morbidity among transplant recipients. The efficacy of second-line treatments v...
A personalized organ-based approach to the selection of therapeutic agents in cGvHD can result in a more favorable patient outcome and achieve a better organ-specific response.
Non-GVHD Enterocolitis Following Cord Blood Transplant Is Real, With Poorly Understood Pathophysiology, and Requires Distinct Management From GVHD, With Eventual Resolution Without Immune Suppression
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723017128?via=ihub
Enterocolitis is common after cord blood transplant (CBT) and a specific, non-GVHD entity with specific histopathologic features ("cord colitis") ha...
Overall survival was superior in the non-GVHD enterocolitis cohort compared with the GVHD group, and the duration of immune suppression was shorter for non-GVHD enterocolitis patients, reflecting the need for different management approaches.